ARTham Therapeutics Inc

2:15 PM - 2:30 PM (JST), Wednesday, March 6, 2019 ・ 2nd Floor
ARTham Therapeutics was launched in Yokohama, Japan in July 2018 with four projects in-licensed from Takeda Pharmaceuticals Company. Series A investors are Takeda, Miyako Capital, SMBC Capital, Mizuho Capital and Oita Venture Capital. Of the four projects, two are clinical candidates. The first clinical candidate, ART-648, for the treatment of NASH, and second, ART-001, for Venous Malformations, that includes orphan indication such as, Klippel Trenaunay syndrome. ART-648 Ph1 was initiated on Jan 8th 2019 and data will be available end of 2Q2019 and expected start for Ph2a is 2H2019. ART-001, Ph1 will be initiated in 1Q2020 post preclinical development activities that involve development of new formulation. We are seeking series B investment and/or strategic partnerships to advance the clinical candidates through later stages of development.
Using repositioning strategies and virtual R&D model, ARTham’s leadership team drives the projects to deliver candidates in clinic for human POC studies. The leadership team has worked together in Takeda for more than 6 years and delivered several clinical candidates in diverse therapeutic areas.
Company Type:
Privately Funded Company
Company HQ State:
Not Provided
Company HQ Country:
Year Founded:
Main Therapeutic Focus:
Lead Product in Development:
ART-648, PDE4 inhibitor for NASH; ART-001, PI3K alpha inhibitor for Venous malformations
Development Phase of Primary Product:
Phase I
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided